IGF-1 LR3 is an 83 amino acid analogue of human IGF-1 that has been modified to include a 13 amino acid extension on its N-Terminus and the substitution of an Arginine amino acid for Glutamine at position 3. While IGF-1 LR3 is comprised of the the complete human IGF-1 sequence, these modifications have rendered the LR3 version to be much more potent than IGF-1 in-vitro and in-vivo. The result of these modifications is that IGF-1 LR3 does not bind as strongly to the IGFBPs, which modify the biological actions of IGF-1. Resultantly, IGF-1 LR3 binds to the type 1 IGF-1 receptor with similar affinity to that of wild type IGF-1, but with higher biological activity and has several advantages over recombinant insulin.
Usage : Increasing the performance of the human amino acid exchange, the increased level of protein synthesis, increase RNA synthesis, facilitating transport of glucose and fat metabolism, stimulating the generation of protein, reduction of protein breakdown.
